SMMT Overview
Upcoming Projects (SMMT)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (SMMT)
-
Discussing Summit's recent Phase 3 HARMONi-2 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1- positive Advanced NSCLC
Ticker: SMMT
Executed On: Sep 18, 2024 at 04:00 PM EDT -
Discussing Summit's ivonescimab and the results of the HARMONi-2 trial in Non-Small Cell Lung Cancer (NCSLC)
Tickers: SMMT, MRK
Executed On: Jun 13, 2024 at 04:00 PM EDT
Expired Projects (SMMT)
-
Discussing the Potential of Summit's (SMMT) Ezutromid in Duchenne Muscular Dystrophy After Initiation of Phase 2 Enrollment
Tickers: SMMT, SRPT
Execute By: Jan 04, 2017
Upcoming & Overdue Catalysts (SMMT)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (SMMT)
-
Summit Therapeutics (SMMT) set to begin Phase 3 trial on antibiotic Ridinilazole in treating C. difficile 1Q 2019
Ticker: SMMT
Occurred on: Feb 13, 2019 -
Phase 2 48-week top-line data of Summit's(SMMT) Ezutromid in treating Duchenne muscular dystrophy due 3Q 2018 - Discontinued
Ticker: SMMT
Occurred on: Jun 29, 2018 -
New Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation in Phase 2 Clinical Trial in DMD
Ticker: SMMT
Occurred on: Feb 26, 2018 -
Interim 24-Week Data from PhaseOut DMD released by Summit Therapeutics (SMMT)
Ticker: SMMT
Occurred on: Jan 25, 2018 -
Top-line data from the Open label Phase 2 trial comparing ridinilazole to fidaxomicin is expected to be reported in Q2 2017
Tickers: SMMT, MRK
Occurred on: Oct 09, 2017 -
Data from First Set of 24-week Biopsies Expected Q2 or Q3 for UK Enrolled DMD patients in the Ongoing PhaseOut DMD trial
Tickers: SMMT, BMRN, SRPT, PTCT
Occurred on: Jun 22, 2017 -
Summit Enrolls Patients in the United States Into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients With DMD
Ticker: SMMT
Occurred on: Nov 16, 2016 -
Summit's (SMMT) EZUTROMID Granted Rare Pediatric Disease Designation from FDA in Treatment of Duchenne Muscular Dystrophy
Ticker: SMMT
Occurred on: Sep 27, 2016 -
Summit's (SMMT) EZUTROMID Granted Fast Track Designation By FDA for Duchenne Muscular Dystrophy
Ticker: SMMT
Occurred on: Sep 26, 2016 -
Summit’s IND Cleared by FDA Allowing Expansion of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid
Ticker: SMMT
Occurred on: Apr 26, 2016 -
Summit Announce Ridinilazole Preserves the Gut Microbiome of Patients with C. difficile Infection
Ticker: SMMT
Occurred on: Mar 07, 2016
Strategic Initiatives (SMMT)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
